Incidental Breast Uptake on a Bone Scan
A 62-year-old woman is referred for a whole-body bone scan to evaluate low back pain. She has a history of right-sided breast cancer treated with lumpectomy and radiation 8 years ago. Tc-99m MDP, 740 MBq, is administered IV and imaging begins 3 hours later. On the anterior view, a focal area of increased tracer uptake is seen in the right breast region, corresponding to the prior lumpectomy site. There is no corresponding abnormality on the lateral view beyond the expected soft-tissue activity. The lumbar spine shows mild degenerative changes. The patient reports no new breast symptoms, no palpable mass, and no skin changes. She asks whether the breast finding means her cancer has returned. The referring physician has ordered only the bone scan and has not requested additional imaging.
1. How should the technologist classify and communicate the right breast finding, and what is the appropriate next step before the study is finalized?
Read the worked answer
The finding is an incidental area of soft-tissue uptake in the breast, at the site of prior lumpectomy and radiation. In bone scintigraphy, focal breast uptake can reflect benign processes such as prior surgery, radiation change, infection, or fibrocystic disease, but it can also occur with breast malignancy. Because the bone scan is not a dedicated breast imaging study, the technologist cannot characterize it.
The technologist should not dismiss it as artifact. The correct action is to document the finding clearly, note the location and its relationship to the known surgical/radiation site, and bring it to the attention of the interpreting physician (radiologist/nuclear medicine physician) before the report is signed. The technologist should not independently order mammography or ultrasound, and should not tell the patient the cancer has returned. If the physician agrees, the report can recommend clinical correlation and dedicated breast imaging (mammography/ultrasound) with the patient's oncology team. The patient's question should be answered by directing her to the interpreting physician or her referring clinician, not by technologist speculation.
2. The patient asks the technologist directly, "Does this mean my cancer is back?" What is the most appropriate response, and why?
Read the worked answer
The technologist should respond empathetically but avoid interpretation: explain that the scan shows an area of increased tracer activity at the site of her previous treatment, that this type of finding can have several causes including benign post-treatment changes, and that the physician who interprets the scan will review it and communicate with her referring doctor. The technologist should not say it is definitely benign or definitely malignant.
This boundary exists because image interpretation and diagnosis are the responsibility of the interpreting physician, and because the technologist lacks the clinical context (exam findings, prior imaging, tumor markers) needed to judge significance. Offering false reassurance or alarming speculation both harm the patient and exceed scope. The technologist can support the patient by acknowledging her concern, confirming the finding will be reported, and encouraging her to discuss results with her oncologist.